FNY Investment Advisers LLC Purchases 3,000 Shares of Bausch + Lomb Corporation $BLCO

FNY Investment Advisers LLC increased its position in Bausch + Lomb Corporation (NYSE:BLCO) by 93.8% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,200 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. FNY Investment Advisers LLC’s holdings in Bausch + Lomb were worth $80,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Allianz Asset Management GmbH lifted its stake in shares of Bausch + Lomb by 136.6% in the 2nd quarter. Allianz Asset Management GmbH now owns 769,000 shares of the company’s stock valued at $10,005,000 after purchasing an additional 444,000 shares during the period. Blue Trust Inc. lifted its stake in shares of Bausch + Lomb by 58.5% in the 2nd quarter. Blue Trust Inc. now owns 4,502 shares of the company’s stock valued at $59,000 after purchasing an additional 1,662 shares during the period. Ridgewood Investments LLC purchased a new position in shares of Bausch + Lomb in the 2nd quarter valued at approximately $26,000. Goldman Sachs Group Inc. lifted its stake in shares of Bausch + Lomb by 428.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after purchasing an additional 242,993 shares during the period. Finally, Ellsworth Advisors LLC lifted its stake in shares of Bausch + Lomb by 10.0% in the 1st quarter. Ellsworth Advisors LLC now owns 40,516 shares of the company’s stock valued at $587,000 after purchasing an additional 3,672 shares during the period. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Bausch + Lomb Stock Up 0.2%

Shares of NYSE:BLCO opened at $15.75 on Friday. The stock has a fifty day simple moving average of $14.92 and a two-hundred day simple moving average of $13.42. The stock has a market capitalization of $5.58 billion, a price-to-earnings ratio of -20.19, a PEG ratio of 1.72 and a beta of 0.63. Bausch + Lomb Corporation has a 12-month low of $10.45 and a 12-month high of $20.94. The company has a current ratio of 1.55, a quick ratio of 0.98 and a debt-to-equity ratio of 0.76.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Bausch + Lomb had a positive return on equity of 2.33% and a negative net margin of 5.58%.The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Bausch + Lomb Corporation will post 0.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wells Fargo & Company raised their target price on Bausch + Lomb from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Citigroup restated a “neutral” rating on shares of Bausch + Lomb in a research note on Tuesday, October 7th. Evercore ISI raised their target price on Bausch + Lomb from $16.50 to $17.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bausch + Lomb in a research note on Wednesday, October 8th. Finally, Morgan Stanley lifted their price objective on Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Bausch + Lomb currently has a consensus rating of “Hold” and an average target price of $15.70.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.